Cargando…

Suppression of Allograft Fibrosis by Regulation of Mammalian Target of Rapamycin-Related Protein Expression in Kidney-Transplanted Recipients Treated with Everolimus and Reduced Tacrolimus

BACKGROUND: Although renoprotective effects of everolimus (EVR) in kidney transplantation (KTx) have been widely reported, its pathophysiological mechanism remains unclear. MATERIAL/METHODS: We compared changes in eGFR (ΔGFR, ml/min/1.73 m(2)) and the ratio of the fibrotic area in biopsy specimens (...

Descripción completa

Detalles Bibliográficos
Autores principales:	Nishioka, Shun, Ishimura, Takeshi, Endo, Takahito, Yokoyama, Naoki, Ogawa, Satoshi, Fujisawa, Masato
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	International Scientific Literature, Inc. 2021
Materias:	Original Paper
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7812696/ https://www.ncbi.nlm.nih.gov/pubmed/33431785 http://dx.doi.org/10.12659/AOT.926476

Ejemplares similares

Pantoprazole Does not Affect Serum Trough Levels of Tacrolimus and Everolimus in Liver Transplant Recipients
por: Bremer, Sebastian C. B., et al.
Publicado: (2018)

Tacrolimus-induced gingival hyperplasia and recovery from tacrolimus to everolimus switching
por: Oral, Alihan, et al.
Publicado: (2019)

Long-Term Effects of Everolimus-Facilitated Tacrolimus Reduction in Living-Donor Liver Transplant Recipients with Hepatocellular Carcinoma
por: Sapisochin, Gonzalo, et al.
Publicado: (2022)

Functional and histological improvement after everolimus rescue of chronic allograft dysfunction in renal transplant recipients
por: Chow, Kai Ming, et al.
Publicado: (2015)

Everolimus With Reduced Tacrolimus Improves Renal Function in De Novo Liver Transplant Recipients: A Randomized Controlled Trial
por: De Simone, P, et al.
Publicado: (2012)

Everolimus for the treatment of CD20+ diffuse large B-cell lymphoma in a renal allograft recipient
por: Kute, V. B., et al.
Publicado: (2012)

Mechanistic analyses in kidney transplant recipients prospectively randomized to two steroid free regimen—Low dose Tacrolimus with Everolimus versus standard dose Tacrolimus with Mycophenolate Mofetil
por: Traitanon, Opas, et al.
Publicado: (2019)

Immunological Monitoring of Renal Transplant Recipients to Predict Acute Allograft Rejection Following the Discontinuation of Tacrolimus
por: Kreijveld, Ellen, et al.
Publicado: (2008)

Open-Label, Randomized Study of Transition From Tacrolimus to Sirolimus Immunosuppression in Renal Allograft Recipients
por: Tedesco-Silva, Helio, et al.
Publicado: (2016)

The Impact of Single Nucleotide Polymorphisms on the Pharmacokinetics of Tacrolimus in Kidney Allograft Recipients of Northern-West, Iran
por: Jabbari Hagh, Elaheh, et al.
Publicado: (2023)

The Role of the Mammalian Target of Rapamycin (mTOR) in Pulmonary Fibrosis
por: Lawrence, Jessica, et al.
Publicado: (2018)

Everolimus/prednisolone/tacrolimus: COVID-19 infection: case report
Publicado: (2021)

The role of everolimus in treatment of cardiac allograft vasculopathy
por: Watanabe, Tetsu
Publicado: (2013)

Prediction of Tacrolimus Exposure by CYP3A5 Genotype and Exposure of Co-Administered Everolimus in Japanese Renal Transplant Recipients
por: Kagaya, Hideaki, et al.
Publicado: (2018)

Combination of everolimus and tacrolimus: a potentially effective regimen for recalcitrant psoriasis
por: Wei, Kai-Che, et al.
Publicado: (2015)

Tacrolimus-Induced Salt Losing Nephropathy Resolved After Conversion to Everolimus
por: Sayin, Burak
Publicado: (2015)

Tremor Induced by Cyclosporine, Tacrolimus, Sirolimus, or Everolimus: A Review of the Literature
por: Wagle Shukla, Aparna, et al.
Publicado: (2023)

Conversion to mammalian target of rapamycin inhibitors in kidney transplant recipients with de novo cancers
por: Cheung, Chi Yuen, et al.
Publicado: (2017)

Impact of maintenance immunosuppressive therapy on the fecal microbiome of renal transplant recipients: Comparison between an everolimus- and a standard tacrolimus-based regimen
por: Zaza, Gianluigi, et al.
Publicado: (2017)

Phase II Study of BEZ235 versus Everolimus in Patients with Mammalian Target of Rapamycin Inhibitor‐Naïve Advanced Pancreatic Neuroendocrine Tumors
por: Salazar, Ramon, et al.
Publicado: (2017)

Everolimus, a mammalian target of rapamycin inhibitor, ameliorated streptozotocin-induced learning and memory deficits via neurochemical alterations in male rats
por: Fanoudi, Sahar, et al.
Publicado: (2018)

Abstract: Belatacept and Rapamycin with Short-Term Use of Tacrolimus Delay Allograft Rejection in a Novel, Large Animal Vascularized Composite Allotransplantation Model
por: Elgendy, Tarek, et al.
Publicado: (2018)

Efficacy and Safety of Everolimus With Reduced Tacrolimus in Liver Transplant Recipients: 24-month Results From the Pooled Analysis of 2 Randomized Controlled Trials
por: Lee, Sung-Gyu, et al.
Publicado: (2020)

Everolimus/prednisone/tacrolimus: Primary lung adenocarcinoma and lymphangitic carcinomatosis: case report
Publicado: (2018)

Utilization of Mycophenolic Acid, Azathioprine, Tacrolimus, Cyclosporin, Sirolimus, and Everolimus: Multinational Study
por: Sahman, Majda, et al.
Publicado: (2021)

Addition of the mammalian target of rapamycin inhibitor, everolimus, to consolidation therapy in acute myeloid leukemia: experience from the UK NCRI AML17 trial
por: Burnett, Alan K, et al.
Publicado: (2018)

Everolimus is better than rapamycin in attenuating neuroinflammation in kainic acid-induced seizures
por: Yang, Ming-Tao, et al.
Publicado: (2017)

Differential Antitumoral Properties and Renal-Associated Tissue Damage Induced by Tacrolimus and Mammalian Target of Rapamycin Inhibitors in Hepatocarcinoma: In Vitro and In Vivo Studies
por: Navarro-Villarán, Elena, et al.
Publicado: (2016)

Influence of CYP3A5 polymorphism on tacrolimus drug dosing in Indian renal allograft recipients: initial experience
por: Patel, Mohan, et al.
Publicado: (2014)

Effect of Everolimus with Low-Dose Tacrolimus on Development of New-Onset Diabetes After Transplantation and Allograft Function in Kidney Transplantation: A Multicenter, Open-Label, Randomized Trial
por: Kim, Hyung Duk, et al.
Publicado: (2021)

Tacrolimus, Sirolimus and Everolimus Doses in HIV-Infected Solid-Organ Recipients, Requiring a Cobicistat-Based Antiretroviral Regimen: Report of Three Cases and Review
por: Diaz, Natalia A., et al.
Publicado: (2021)

Effect of Calcineurin Inhibitors and Mammalian Target of Rapamycin Inhibitors on the Course of COVID-19 in Kidney Transplant Recipients
por: Hasbal, Nuri Baris, et al.
Publicado: (2021)

Wound complications frequency in heart transplant recipients on mammalian target of rapamycin inhibitors: A meta‐analysis
por: Zhu, Shenyu, et al.
Publicado: (2023)

Early Switch From Tacrolimus to Everolimus After Liver Transplantation: Outcomes at 2 Years
por: Saliba, Faouzi, et al.
Publicado: (2019)

Conversion to Everolimus was Beneficial and Safe for Fast and Slow Tacrolimus Metabolizers after Renal Transplantation
por: Thölking, Gerold, et al.
Publicado: (2020)

Alteration of urinary neutrophil gelatinase–associated lipocalin as a predictor of tacrolimus-induced chronic renal allograft fibrosis in tacrolimus dose adjustments following kidney transplantation
por: Chancharoenthana, Wiwat, et al.
Publicado: (2018)

Drug–Drug Interaction between Tacrolimus and Vonoprazan in Kidney Transplant Recipients
por: Suzuki, Yoshiharu, et al.
Publicado: (2021)

A Randomized Multicenter Study Comparing a Tacrolimus-Based Protocol with and without Steroids in HCV-Positive Liver Allograft Recipients
por: Neumann, Ulf, et al.
Publicado: (2012)

Influence of CYP3A5 and ABCB1 Polymorphism on Tacrolimus Drug Dosing in South Indian Renal Allograft Recipients
por: Fernando, M. Edwin, et al.
Publicado: (2019)

The Association between CDKAL1 Gene rs10946398 Polymorphism and Post-Transplant Diabetes in Kidney Allograft Recipients Treated with Tacrolimus
por: Dziedziejko, Violetta, et al.
Publicado: (2023)

Cannot write session to /tmp/vufind_sessions/sess_ia09529rpsosk1uh9enfg6ctin